ProCE Banner Activity

My Thoughts on Key Studies in Myeloma From ASH 2019

Clinical Thought
Did you see the latest clinical data in myeloma? In this commentary, Sagar Lonial, MD, discusses the key studies on myeloma that were recently presented at ASH 2019.

Released: February 26, 2020

Expiration: February 24, 2021

No longer available for credit.

Share

Faculty

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company

Faculty Disclosure

Primary Author

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received consulting fees from Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Merck, Novartis, and Takeda and funds for research support from Celgene, Janssen, and Takeda.